First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
/PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is...
Source: prnewswire.com